Venus Remedies has entered into an exclusive license agreement with lnfex Therapeutics, a UK-based anti-infectives specialist for the clinical development of MET-X. This agreement authorizes the company to spearhead the clinical development, registration, and commercialization of MET-X, an innovative Metallo-Beta-Lactamase (MBL) inhibitor. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria, with the company holding exclusive marketing rights within India.
Under the terms of the agreement, the company will commence with a Phase I involving healthy volunteers in India, evaluating MET-X in combination with meropenem. Following successful Phase I outcome, the focus will shift to Phase II/III trials targeting drug-resistant Complicated Urinary Tract Infections (cUTls), prevalent in hospital settings.
This strategic move is aligned with the company’s extensive experience in antibiotic R&D and critical care, enhancing its leadership in Indian critical care landscape. The company’s formidable position in meropenem marketing and manufacturing will facilitate the integration of MET-X in existing and prospective antibiotic strategies.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1696.65 |
| Dr. Reddys Lab | 1218.30 |
| Cipla | 1226.65 |
| Zydus Lifesciences | 936.00 |
| Lupin | 2339.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: